Janux Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Janux Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2024.
  • Janux Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$20.2M, a 71.9% decline year-over-year.
  • Janux Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$69M, a 18.4% decline year-over-year.
  • Janux Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$69M, a 18.4% decline from 2023.
  • Janux Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$58.3M, a 7.56% increase from 2022.
  • Janux Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$63.1M, a 93% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$69M -$10.7M -18.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 -$58.3M +$4.77M +7.56% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 -$63.1M -$30.4M -93% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 -$32.7M -$25.9M -382% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-10
2020 -$6.78M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.